Atlas Trials

Diwakar Davar

13 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Diwakar Davar

RecordFirmDate
Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) (NCT06499896)Diwakar Davar2027-01-23
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (NCT07223424)Diwakar Davar2025-11-04
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (NCT06070012)Diwakar Davar2025-08-18
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma (NCT06030037)Diwakar Davar2025-03-11
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC (NCT05669846)Diwakar Davar2025-01-08
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma (NCT05130177)Diwakar Davar2022-03-16
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (NCT05061017)Diwakar Davar2021-12-09
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) (NCT04808999)Diwakar Davar2021-05-11
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab (NCT04401995)Diwakar Davar2020-09-02
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma (NCT04139902)Diwakar Davar2020-06-12

Track Diwakar Davar automatically

Every clearance here is in the API, with alerts when new ones post.